Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Here are five things to know about the company's de novo strategy: 1. USPI added nearly 70 ASCs in 2024, remaining "very active in both [mergers and acquisitions] and de novo development." The company ...
Miami's Community Newspapers on MSN6h
Locality Bank Completes De Novo Period, Marking Historic Milestone for South Florida Business CommunityLocality Bank officially completed its de novo period on January 12, 2025, marking a significant milestone and the end of the initial three-year supervisory phase for newly chartered banks, ...
HIGHLIGHTS Geological and geochemical sampling campaigns designed to guide effective targeting for drill programs in Q2 2025 ...
The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback